• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?

    7/3/24 1:04:01 PM ET
    $ACHR
    $AMGN
    $LCID
    $LLY
    Aerospace
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACHR alert in real time by email

    The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector activity, which experienced its worst contraction since May 2020.

    Market-implied odds of a Fed rate cut in September rose from 65% to 72%, according to CME Group’s FedWatch tool, with traders pricing in more than 50 basis points of rate cuts by year end, implying two fully priced rate reductions by the Fed.

    Risk sentiment was particularly strong ahead of the Federal Open Market Committee (FOMC) Minutes, slated to be released at 2:00 p.m. ET.

    Nvidia Corp. (NASDAQ:NVDA) and the chip making industry, as tracked by the iShares Semiconductor ETF (NYSE:SOXX), rebounded, up 3.7% and 1.9%, respectively.

    Strong gains also stemmed from gold miners, with the VanEck Gold Miners ETF (NYSE:GDX) up 4.2%, eyeing one of the best-performing sessions year to date, driven by rising metal prices.

    Expectations of lower interest rates fueled gold prices up by 1.4%, silver up by 3.5%, and copper up by 2.6%.

    Treasury yields weakened sharply, with both the 10-year and 30-year yields down 7 basis points. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) rose 1.1%, rallying the most since June 13.

    However, the crypto market faltered, with Bitcoin (CRYPTO: BTC) down 2.7% to $60,450.

    Wednesday’s Performance In Major US Indices, ETFs

    Major IndicesPrice1-day %chg
    Nasdaq 10020,168.730.8%
    S&P 5005,531.060.4%
    Russell 2000202.160.1 %
    Dow Jones39,273.72-0.1%
    Updated at 12:28 p.m. ET

    According to Benzinga Pro data:

    • The SPDR S&P 500 ETF Trust (NYSE:SPY) was 0.3% higher to $550.85.
    • The SPDR Dow Jones Industrial Average (NYSE:DIA) was 0.2% lower to $392.45.
    • The tech-heavy Invesco QQQ Trust (ARCA: QQQ) was 0.8% higher to $490.70.
    • Sector-wise, the Technology Discretionary Select Sector SPDR Fund (NYSE:XLK) outperformed, up by 1.3%, while the Health Care Select Sector SPDR Fund (NYSE:XLV) lagged, falling 1%.

    Wednesday’s Stock Movers

    • Weight-loss giant Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) tumbled 1.9% and 4% respectively, after a study conducted by the Massachusetts Eye and Ear showed that Ozempic and Wegovy are linked to higher risk of blinding eye conditions. Amgen Inc. (NASDAQ:AMGN) and Viking Therapeutics Inc. (NASDAQ:VKTX) also fell 1.9% and 2.2%, respectively.
    • Tesla Inc. (NASDAQ:TSLA) shares continued their upward momentum from Tuesday, rallying 5.5% after the electric-vehicle maker’s quarterly deliveries came in better than expected.
    • Other EV-related stocks also rallied, with Lucid Group Inc. (NASDAQ:LCID) up 8%, Archer Aviation Inc. (NYSE:ACHR) up 15%.
    • Paramount Global (NASDAQ:PARA) surged over 7% following rumors from the Wall Street Journal that Skydance is once again interested in the deal to buy Paramount’s controlling company, National Amusements.
    • Constellation Brands Inc. (NYSE:STZ) fell 4.4%, marking the worst session since October 2023, amid lower-than-expected revenue last quarter.

    Read Now:

    • June Jobs Report Preview: Cooling Labor Market Trends May Further Bolster Rate Cut Hopes
    Get the next $ACHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHR
    $AMGN
    $LCID
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Amgen Inc.
    $AMGN
    2/20/2026$185.00Equal Weight
    Barclays
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Novo Nordisk A/S
    $NVO
    2/12/2026Underperform → Hold
    Jefferies
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Novo Nordisk A/S
    $NVO
    1/27/2026Neutral
    Citigroup
    Amgen Inc.
    $AMGN
    1/20/2026$335.00Outperform → Mkt Perform
    Bernstein
    NVIDIA Corporation
    $NVDA
    1/15/2026$240.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $ACHR
    $AMGN
    $LCID
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Amgen with a new price target

    Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:35 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $ACHR
    $AMGN
    $LCID
    $LLY
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    2/20/26 7:45:51 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Amgen Inc.

    8-K - AMGEN INC (0000318154) (Filer)

    2/19/26 4:27:56 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form FWP filed by Amgen Inc.

    FWP - AMGEN INC (0000318154) (Subject)

    2/17/26 5:14:08 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Finance & CAO Busch Matthew C. sold $375,790 worth of shares (1,000 units at $375.79), decreasing direct ownership by 23% to 3,423 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    2/20/26 7:43:21 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief People Officer Dozier Eric gifted 481 shares, decreasing direct ownership by 3% to 14,455 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/19/26 4:18:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.16% to 2,966 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:27:23 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Takes Flight: Five Companies Advancing Defense and Aerospace Intelligence

    Issued on behalf of Starfighters Space, Inc.VANCOUVER, Feb. 20, 2026 /CNW/ -- USA News Group News Commentary – The U.S. Department of Defense recently requested $66 billion in IT spending for its fiscal 2026, signalling a $1.8 billion increase from the prior year, with artificial intelligence topping the priority list across every service branch[1]. A new industry forecast projects the global AI in defense and aerospace market will grow from $4.2 billion to $42.8 billion by 2036, a tenfold expansion driven by autonomous systems and real-time intelligence processing[2]. Five companies operating at the intersection of aerospace, AI, and national security are Starfighters Space (NYSE:FJET), Arc

    2/20/26 9:15:00 AM ET
    $ACHR
    $AVAV
    $FJET
    Aerospace
    Industrials
    Air Freight/Delivery Services
    Consumer Discretionary

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

    Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years  Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma

    2/19/26 12:15:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    Financials

    Live finance-specific insights

    View All

    Archer To Report Fourth Quarter and Full Year 2025 Operating Update and Financial Results on March 2, 2026

    Archer Aviation Inc. (NYSE:ACHR) will report its fourth quarter and full year 2025 operating update and financial results after market close on Monday, March 2, 2026. The company will host a live webcast to discuss its results at 2:00 p.m. Pacific Time. The live webcast and replay will be available at investors.archer.com. To listen to the conference call, dial +1 646-844-6383 (domestic) or +1 833-470-1428 (international), and enter the access code 043388. Archer will also utilize Say Technologies' Q&A Platform to allow shareholders to submit and vote on questions by visiting https://app.saytechnologies.com/archer-aviation-2025-q4. About Archer Archer is designing and developing the

    2/12/26 5:30:00 PM ET
    $ACHR
    Aerospace
    Industrials

    Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended

    2/11/26 4:16:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

    Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time  SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

    2/4/26 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Constellation Brands Announces CEO Succession Plan

    ROCHESTER, N.Y., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, today announced that its Board of Directors has appointed Nicholas Fink as the company's next President and Chief Executive Officer, effective April 13, 2026. Fink, a member of Constellation's Board of Directors since 2021, will succeed current President and CEO Bill Newlands, and will continue to serve on the company's Board. Newlands will step down as President and CEO effective April 13, 2026, and will continue to serve as a strategic advisor over the next several months to help ensure a smooth transition of leadership responsibilities. In addition, Newlands will

    2/12/26 4:16:01 PM ET
    $STZ
    Beverages (Production/Distribution)
    Consumer Staples

    Lucid Announces Appointment of Neil Marsons as Senior Vice President of Supply Chain

    NEWARK, Calif., Feb. 9, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced electric vehicles, today announced Neil Marsons has joined the organization as the Senior Vice President of Supply Chain. Bringing more than 20 years of experience to the role, Marsons will be responsible for expanding and strengthening the company's global supply chain, as well as closely partnering across the organization to support production at the company's facilities in Arizona and Saudi Arabia. Previously, Marsons served as the Group Chief Procurement Officer

    2/9/26 10:49:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHR
    $AMGN
    $LCID
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Archer Aviation Inc.

    SC 13D/A - Archer Aviation Inc. (0001824502) (Subject)

    11/18/24 9:40:14 PM ET
    $ACHR
    Aerospace
    Industrials

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Constellation Brands Inc.

    SC 13G - CONSTELLATION BRANDS, INC. (0000016918) (Subject)

    11/13/24 12:49:26 PM ET
    $STZ
    Beverages (Production/Distribution)
    Consumer Staples